Generics - Oncology, Markets & Marketing

Filter

Popular Filters

1 to 25 of 32 results

Intas reinforces cancer range with the first time launch of Azadine in India

25-06-2014

Indian drugmaker Intas Pharmaceuticals says it has reinforced its oncology product range by successfully…

AzadineCelgeneGenericsIndiaIntas PharmaceuticalsMarkets & MarketingOncologyVidaza

Mylan launches generic Paraplatin Injection in USA

Mylan launches generic Paraplatin Injection in USA

09-06-2014

US generics major Mylan has launched carboplatin injection, 50mg/5ml, in multi-dose vials, which is the…

Bristol-Myers SquibbGenericsMarkets & MarketingMylanOncologyParaplatinRegulationUSA

Hospira refutes high pricing of paclitaxel during drug shortage

Hospira refutes high pricing of paclitaxel during drug shortage

08-06-2014

The Canadian subsidiary of USA-based injectable generic drugs specialist Hospira has refuted press reports…

CanadaGenericsHospiraMarkets & MarketingOncologyPaclitaxelPricing

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

26-02-2014

The local subsidiary of Israeli generics giant Teva Pharmaceutical Industries has launched Lonquex (lipegfilgrastim)…

AmgenBiosimilarsGenericsLonquexMarkets & MarketingNorthern EuropeOncologyTeva Pharmaceutical IndustriesUK

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

Teva updates on Lonquex and Granix launches

Teva updates on Lonquex and Granix launches

18-11-2013

Israel-based Teva Pharmaceutical Industries announced two significant additions to its global oncology…

balugrastimBiosimilarsEuropeGenericsLonquexMarkets & MarketingNorth AmericaOncologyRegulationTeva Pharmaceutical Industries

Biocad enters deal for exporting rituximab biosimilar to Turkey

22-08-2013

Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

Generic Temodar launches in USA

13-08-2013

Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) and Perrigo (NYSE: PRGO;TASE) today…

GenericsMarkets & MarketingMerck & CoNorth AmericaOncologyPerrigoTemodarTeva Pharmaceutical Industries

Cancer treatments "unaffordable" and will drive rapid transition to generics and market decline, says GlobalData

10-05-2013

The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and health…

BiotechnologyGenericsGlobalMarkets & MarketingOncologyPharmaceuticalPricing

Sagent Pharma launches generic Zometa in USA; amends supply deal with Actavis

07-03-2013

Privately-held US specialty pharmaceutical company Sagent Pharmaceuticals has announced the approval…

ActavisGenericsMarkets & MarketingNorth AmericaNovartisOncologyProductionSagent PharmaceuticalsZometa

Briefs: Ablynx inks research deal with Spirogen; Solent Pharma debuts

25-02-2013

Belgium drug developer Ablynx (Euronext Brussels: ABLX]) has entered into a research collaboration with…

AblynxGenericsidebenoneIdecortexLicensingMarkets & MarketingNeurologicalOncologyPharmaceuticalResearchSolent PharmaSpirogen

Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021

04-11-2012

Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Biosimilar versions of MAbs for cancer forecast to garner sales of $4.9 billion in 2021

28-10-2012

While branded versions of monoclonal antibodies for cancer are expected to maintain sales of $6.7 million…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Hospira re-launches generic Eloxatin in USA

12-08-2012

US injectable drugs and infusion specialist Hospira (NYSE: HSP) last week announced the US re-launch…

GenericsMarkets & MarketingNorth AmericaOncology

Taiwan's ScinoPharm invests NT$1.1 billion in cytotoxic injectables facility

03-07-2012

Taiwan based active pharmaceutical ingredients maker ScinoPharm (TWSE: 1789) says it plans to invest…

Asia-PacificFinancialGenericsMarkets & MarketingOncologyScinoPharm

Indonesian $16 million NSCLC drugs market kept afloat by high-priced branded drugs

08-06-2012

Branded drugs for the treatment of non-small cell lung cancer (NSCLC) in Indonesia cost almost three…

Asia-PacificGenericsHealthcareMarkets & MarketingOncologyPharmaceutical

Merck KGaA collaborates with Dr Reddy's on biosimilars

07-06-2012

With the aim of capitalizing on the batch of patent expires for blockbuster biotechnology-based drugs…

BiotechnologyDr Reddy's LaboratoriesGenericsMarkets & MarketingMerck KGaAMerck SeronoOncologyResearch

Prodigy Generics and eVenus launch injectable generic Camptosar in USA

24-05-2012

Prodigy Generics, a division of Prodigy Health Supplier Corp (PHS), has launched injectable irinotecan,…

Camptosar InjectioneVenusGenericsirinotecanMarkets & MarketingNorth AmericaOncologyPfizerProdigy Generics

US FDA acts on cancer drugs shortages; move applauded by GPhA

22-02-2012

The US Food and Drug Administration this week spelt out a series of steps to increase the supply of critically…

APP PharmaceuticalsDoxilGenericsHospiraMarkets & MarketingmethotrexateNorth AmericaOncologyPharmaceuticalRegulationSun Pharmaceutical Industries

Generic launches of irinotecan, Primaxin and Merrem

08-02-2012

Japan’s ASKA Pharmaceuticals has announced the launch of irinotecan, the active ingredient of Campto…

ActavisAntibiotics and Infectious diseasesAPP PharmaceuticalsASKA PharmaceuticalsFresenius KabiGenericsirinotecanMarkets & MarketingMerrem I.V.Oncology

Amgen in cancer biosimilars deal with Watson

20-12-2011

A collaboration has been entered into by Amgen (Nasdaq: AMGN), the world’s largest independent biotech…

AmgenBiotechnologyGenericsGlobalLicensingMarkets & MarketingOncologyWatson Pharmaceuticals

NSCL cancer drug market set to grow 2.5% a year between 2010 and 2020, despite generic erosion

06-12-2011

Despite the arrival of generic competition – and ensuing sales erosion for several key agents used…

GenericsMarkets & MarketingOncologyPharmaceutical

1 to 25 of 32 results

Back to top